S-oxprenolol - Actimed Therapeutics
Alternative Names: ACM-002; FDY 8801Latest Information Update: 06 Sep 2024
At a glance
- Originator Actimed Therapeutics
- Developer Actimed Therapeutics; Faraday Pharmaceuticals
- Class Antihypertensives; Ethers; Ischaemic heart disorder therapies; Phenoxypropanolamines; Propanolamines; Small molecules
- Mechanism of Action Beta adrenergic receptor agonists; Beta adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Cachexia
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 04 Sep 2024 S-oxprenolol - Actimed Therapeutics receives Orphan Drug status for Amyotrophic lateral sclerosis in USA
- 16 Jan 2024 Phase-II clinical trials in Cachexia (unspecified route) prior to January 2024 (Faraday pharmaceuticals pipeline, January 2024)
- 07 Sep 2023 Preclinical trials in Amyotrophic lateral sclerosis in United Kingdom (unspecified route) prior to September 2023 (Actimed Therapeutics pipeline; September 2023)